Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

• Becton, Dickinson and Company recently reported second-quarter earnings that exceeded analyst expectations, posting $3.23 in earnings per share against a consensus estimate of $3.14, while also generating $4.98 billion in revenue, which surpassed the projected $4.89 billion and represented a 5.4% increase compared to the same period last year.
• The company has demonstrated strong operational momentum by raising its full-year 2026 earnings per share guidance to a range of $12.62 to $12.72, which is above the current analyst consensus estimate of $12.56, suggesting management confidence in continued performance.
• Investors can benefit from a stable income stream as the company recently declared a quarterly dividend of $1.05 per share, which will be paid on September 30, 2026, resulting in an annualized yield of approximately 2.36% based on the current stock price of $185.78.
• The stock has shown significant upward momentum, trading at $185.78 as of September 15, 2026, which is well above its 200-day moving average of $160.49 and its 50-day moving average of $173.06, indicating a strong bullish trend among technical traders.
• Becton, Dickinson and Company is expanding its market presence in healthcare automation with the deployment of the BD Vmax 160, a next-generation pharmacy automation robot that helps health systems manage complex specialty therapies and refrigerated medications, positioning the company for growth in advanced medical technology.